Clascoterone

Clascoterone (cortexolone 17α-propionate) is the first topical androgen receptor (AR) antagonist with Phase 3 data behind it — essentially a DHT-shaped decoy that sits on the receptor in scalp and sebaceous tissue without ever meaningfully entering systemic circulation. For the bodybuilding and looksmaxxing reader, that last part is the whole point: it provides follicle-level androgen blockade without the libido, fertility, or mood trade-offs that come with oral fin/dut or spironolactone.

Local Androgen Receptor Antagonism at the Follicle#

The core mechanism is competitive AR antagonism in scalp dermal papilla cells (DPCs). DHT drives androgenetic alopecia by binding AR in genetically susceptible DPCs, which then issue paracrine "miniaturize" signals to the surrounding follicle. Clascoterone competes for that same receptor pocket — occupying it without triggering productive transcription. In vitro, its AR-antagonist potency in DPC reporter assays is comparable to finasteride's downstream effect, but achieved through direct receptor blockade rather than upstream 5α-reductase inhibition. That distinction matters on AAS, where exogenous DHT, trenbolone, and other AR agonists bypass 5α-reductase entirely — a 5-AR inhibitor can't protect you from what isn't being converted, but an AR antagonist at the follicle can.

"Clascoterone demonstrated potent antagonism of androgen receptor-mediated transcriptional activity and effectively suppressed DHT-induced IL-6 production in scalp dermal papilla cells." — Rosette C. et al., J Drugs Dermatol, 2019

Suppression of Paracrine Inflammatory Signalling (IL-6)#

AR activation in DPCs doesn't just miniaturize follicles directly — it also pushes cells to secrete IL-6 and other paracrine mediators that inflame the peri-follicular niche and accelerate the anagen-to-catagen transition. Clascoterone shuts down that DHT-induced IL-6 output in cultured DPCs, and the same mechanism explains its efficacy in acne: in sebocytes, blocking AR transcription collapses both sebum production and the inflammatory cytokine cascade that turns a comedone into a papule. Practically, this is why on-cycle users see it pull double duty — scalp retention and truncal acne control from the same tube of active.

Rapid Esterase Hydrolysis — Why Systemic Sides Don't Happen#

Clascoterone is engineered as a soft drug. Once it crosses the skin barrier, plasma and tissue esterases cleave the 17α-propionate ester almost immediately, yielding cortexolone (11-deoxycortisol) — an inactive metabolite. This is why measurable systemic exposure stays low even with BID application of the 5–7.5% scalp solution, and why trials show no meaningful movement in testosterone, LH, FSH, or cortisol. It's also why there's no QTc signal at supratherapeutic plasma concentrations.

"Topical administration of clascoterone resulted in measurable but low systemic exposure, with no clinically significant effect on the QTc interval observed even at supratherapeutic doses." — Thomson J. et al., Clin Pharmacol Drug Dev, 2021

For the physique-focused user, this is the headline: it provides local AR blockade without touching the HPG axis, which is exactly the profile oral fin/dut can't offer.

Sebaceous Gland AR Blockade (The Acne Mechanism)#

In sebocytes, AR activation drives sebum synthesis and lipogenic gene expression. Clascoterone occupies sebocyte AR the same way it does DPC AR, reducing sebum output and the downstream C. acnes substrate that feeds inflammatory acne. The Phase 3 acne data bore this out at 12 weeks of BID 1% cream.

"Topical clascoterone cream, 1%, was effective and well tolerated in patients with facial acne, showing significantly greater reductions in acne severity compared with vehicle after 12 weeks of treatment." — Hebert A. et al., JAMA Dermatol, 2020

For AAS users, this is the practical win on tren, test, or drol cycles: back and shoulder acne that doesn't respond to benzoyl peroxide or oral doxycycline often does respond to clascoterone because it treats the upstream androgen driver rather than the bacterial and inflammatory aftermath.

Negligible Mineralocorticoid Activity at Labeled Doses#

Because cortexolone is structurally adjacent to aldosterone precursors, there was an early theoretical concern about mineralocorticoid effects or hyperkalemia — the spironolactone-style side profile. That concern hasn't materialized clinically: at labeled topical concentrations, potassium stays in range and no clinically relevant hyperkalemia has been documented.

"Available data indicate no clinically relevant risk of hyperkalemia with topical clascoterone at recommended concentrations, supporting its favorable safety profile." — Del Rosso J. et al., J Clin Aesthet Dermatol, 2023

The practical takeaway: unlike oral spironolactone (which women often take for the same AR-driven indications and which absolutely requires K+ monitoring), topical clascoterone needs no electrolyte workup. That makes it the cleanest AR-antagonist option for a hair stack — the anti-androgen effect stays where you put it, the systemic endocrine picture stays untouched, and the only real commitment is consistency. Expect 12–16 weeks before visible response and, like every other AGA tool, lifetime use to retain what you gain.

Common (most users)#

• Application-site dryness or mild scaling — the 5% scalp solution uses an ethanol/PG vehicle that strips the scalp barrier. Mitigation: apply to dry scalp, let it absorb 5–10 min, follow with a ceramide-based moisturizer at night if needed. Drop to once-daily for a week if irritation flares.
• Mild erythema or pruritus at application site — usually settles within the first 2–4 weeks as the scalp adapts. Mitigation: don't stack application immediately after microneedling (wait 24 h), and don't layer directly on top of a freshly-applied minoxidil solution — space them by 30+ minutes.
• Transient shedding in weeks 4–8 — same synchronized telogen exit you see with any effective AGA treatment entering the follicles into a new anagen cycle. Mitigation: none needed — this is a signal the compound is working. Do not stop. Photos at fixed lighting will confirm the underlying trajectory by month 3.
• Slow visible response — expect minimal visible change before month 3; the real judgment call is at month 6, with continued density gains through month 12. Mitigation: lock in photographic baselines at the same lighting/angle and stop checking the mirror daily.

Uncommon (dose-dependent or individual)#

• Persistent contact dermatitis — more common in users running 7.5–10% compounded solutions or DIY vehicles with aggressive solvent systems. Back off to 5% in a clean vehicle, or switch to alternate-day dosing for 2 weeks before resuming BID.
• Folliculitis or application-site pustules — usually vehicle-related rather than drug-related. Check the carrier; PG-heavy solutions are the common culprit. Switching to a better-formulated vendor usually resolves it.
• Scalp flaking interfering with styling — easily managed by alternating nights with a ketoconazole 2% shampoo, which also has mild independent anti-androgenic activity at the scalp.
• No meaningful hormonal shifts — worth noting in the negative: trial bloodwork showed no clinically relevant changes in testosterone, LH, FSH, or cortisol at labeled topical doses (Dhillon 2020). If you're stacking with oral finasteride or dutasteride and see libido/erectile changes, the oral 5-AR inhibitor is the suspect, not the clascoterone.

"Topical administration of clascoterone resulted in measurable but low systemic exposure, with no clinically significant effect on the QTc interval observed even at supratherapeutic doses." — Thomson et al., Clin Pharmacol Drug Dev (2021)

Rare but serious#

• Theoretical HPA axis suppression at supratherapeutic exposure — the parent drug metabolizes to cortexolone (11-deoxycortisol), raising an early question about mineralocorticoid interference. Published safety review concluded no clinically relevant hyperkalemia risk at labeled concentrations (Del Rosso et al. 2023). Users running 10%+ compounded solutions across the entire scalp are outside the studied envelope — if you're in that territory and develop fatigue, muscle weakness, or palpitations, pull bloods (potassium, cortisol) and drop to 5%.
• Severe allergic contact reaction — rare but real with any topical. Warning signs: spreading erythema beyond the application site, significant swelling, or blistering. Stop immediately.
• QTc effects — not observed even at supratherapeutic plasma exposure in the dedicated TQT study (Thomson et al. 2021). Not a practical concern at any realistic user protocol.

Hard contraindications#

• Pregnancy — topical anti-androgens pose a theoretical risk to a male fetus. Do not use while pregnant, and do not allow skin-to-skin transfer to a pregnant partner before the solution has fully dried.
• Lactation — avoid; not studied.
• Broken, inflamed, or infected scalp skin — absorption increases substantially with barrier disruption, moving you out of the studied low-systemic-exposure envelope. Wait until the scalp is intact before resuming.
• Active scalp infection (bacterial, fungal, or viral) — treat the infection first.
• Do not transfer the solution to a female infant or pregnant partner via pillowcases, hats, or direct contact before it dries.

Gender and fertility considerations#

Clascoterone is one of the few hair compounds that is genuinely appropriate for both sexes at the same dose. Women running a hair stack can use it BID without the virilization-inverse concerns of oral anti-androgens, and without the systemic estrogenic effects of oral spironolactone. It is also the correct tool for men planning near-term conception who cannot run oral finasteride or dutasteride — it does not suppress 5-alpha-reductase systemically, does not affect semen parameters, and does not touch the HPG axis. Women who are or may become pregnant, however, should not use it for the duration of that window.

PCT and on-cycle notes#

No PCT required — clascoterone does not suppress the HPTA. For AAS users, this is the specific niche the compound fills: DHT-derivative cycles (masteron, proviron, trenbolone, anadrol) push AR agonists that bypass 5-alpha-reductase entirely, so oral fin/dut offer no protection against them. Topical AR antagonism at the scalp is the mechanistically correct defense. Clascoterone is the only AR antagonist in this class with Phase 3 safety and efficacy data behind it, making it the lower-volatility choice versus RU58841 or pyrilutamide — and the two can be stacked by users who want heavier coverage during aggressive cycles.